Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B Final Rule Keeps Orphan Drug Exclusion Narrow, Counter To Manufacturers’ Request

This article was originally published in The Pink Sheet Daily

Executive Summary

HRSA’s final rule on the exclusion of orphan drugs from 340B discounts says the exclusion applies only to the FDA-designated orphan indication, not all uses of a drug with a rare-disease designation.

You may also be interested in...



340B Orphan Drug Rule Vacated, Discount Exemption Applies To All Uses

The Pharmaceutical Research and Manufacturers of America wins its challenge to the government's interpretation of the statutory ban on 340B discounts for orphan drugs.

PhRMA Renews Legal Challenge To 340B Orphan Drug Rule

HRSA issued an “interpretive” rule pertaining to discounts on orphan drugs in 340B after a federal judge invalidated the same policy as a “legislative” rule. Now, the pharma trade group asks the court to reject the policy in its “interpretive” form.

340B Orphan Drug Rule Overturned In Court, Putting Future Regs Into Question

A federal court rules in favor of the Pharmaceutical Research and Manufacturers of America in its lawsuit seeking injunction against the 340B discount program’s orphan drug rule. The rule “must be vacated” because HHS lacks the statutory authority to issue the rule, the judge says, giving rise to questions about how upcoming 340B regs will be affected.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel